BIOATLA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.54 USD | +12.89% |
|
+20.67% | +3.25% |
| Mar. 27 | HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating | MT |
| Mar. 26 | Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024 |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,145 | 723.1 | 390.7 | 117.9 | 122.2 | - | - |
| Enterprise Value (EV) 1 | 907 | 478.1 | 175.2 | 117.9 | 122.2 | 122.2 | 122.2 |
| P/E ratio | -30.5 x | -7.11 x | -3.01 x | -0.95 x | -1.31 x | -1.44 x | -1.19 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2,669 x | 2,892 x | - | - | - | - | 11.9 x |
| EV / Revenue | 2,669 x | 2,892 x | - | - | - | - | 11.9 x |
| EV / EBITDA | -39.4 x | -7.6 x | -3.65 x | -0.92 x | -1 x | -1.13 x | - |
| EV / FCF | -31 x | -11.5 x | -4.31 x | -1.13 x | -1.25 x | -1.04 x | -0.85 x |
| FCF Yield | -3.23% | -8.73% | -23.2% | -88.3% | -80% | -96.2% | -118% |
| Price to Book | 5.21 x | -3.64 x | -1.1 x | - | - | - | - |
| Nbr of stocks (in thousands) | 33,664 | 36,836 | 47,352 | 47,936 | 48,106 | - | - |
| Reference price 2 | 34.01 | 19.63 | 8.250 | 2.460 | 2.540 | 2.540 | 2.540 |
| Announcement Date | 3/24/21 | 2/28/22 | 3/23/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.2 | 0.429 | 0.25 | - | - | - | - | 10.3 |
| EBITDA 1 | - | -29.09 | -95.11 | -106.9 | -128.5 | -122.4 | -107.9 | - |
| EBIT 1 | - | -30.1 | -96.44 | -108.1 | -129.7 | -110.1 | -130.8 | -158.5 |
| Operating Margin | - | -7,016.08% | -38,576% | - | - | - | - | -1,538.9% |
| Earnings before Tax (EBT) 1 | - | -35.85 | -95.4 | -106.5 | -123.5 | -106.7 | -127.5 | -156.3 |
| Net income 1 | - | -35.85 | -95.4 | -106.5 | -123.5 | -106.7 | -127.5 | -156.3 |
| Net margin | - | -8,357.34% | -38,160.8% | - | - | - | - | -1,517.21% |
| EPS 2 | -0.5300 | -1.114 | -2.760 | -2.740 | -2.580 | -1.933 | -1.766 | -2.130 |
| Free Cash Flow 1 | - | -36.92 | -63.14 | -90.69 | -104.1 | -97.8 | -117.6 | -143.6 |
| FCF margin | - | -8,606.99% | -25,255.2% | - | - | - | - | -1,394.17% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 10/6/20 | 3/24/21 | 2/28/22 | 3/23/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -23.32 | -23.17 | -24.03 | -28.77 | -25.88 | -28.26 | -28.64 | -36.32 | -34.75 | - | -29 | -30 | -31 | -32 |
| EBIT 1 | -23.7 | -23.49 | -24.35 | -29.06 | -26.18 | -28.56 | -28.93 | -37.2 | -35.02 | -28.54 | -26.22 | -25.85 | -27.7 | -29.88 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -22.93 | -23.39 | -24.25 | -28.91 | -25.78 | -27.54 | -27.46 | -35.75 | -33.32 | -26.92 | -25.28 | -24.96 | -26.83 | -28.74 |
| Net income 1 | -22.93 | -23.39 | -24.25 | -28.91 | -25.78 | -27.54 | -27.46 | -35.75 | -33.32 | -26.92 | -25.28 | -24.96 | -26.83 | -28.74 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.6800 | -0.6300 | -0.6500 | -0.7700 | -0.6900 | -0.6300 | -0.5800 | -0.7500 | -0.7000 | -0.5600 | -0.5416 | -0.4993 | -0.4611 | -0.4567 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 2/28/22 | 5/4/22 | 8/9/22 | 11/3/22 | 3/23/23 | 5/11/23 | 8/1/23 | 11/7/23 | 3/26/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | 238 | 245 | 216 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -36.9 | -63.1 | -90.7 | -104 | -97.8 | -118 | -144 |
| ROE (net income / shareholders' equity) | - | -46.6% | -45.3% | -54.4% | -98.4% | -133% | -120% | - |
| ROA (Net income/ Total Assets) | - | -28.2% | -38.2% | -44.4% | -71.5% | -111% | -102% | - |
| Assets 1 | - | 127.1 | 249.7 | 240.1 | 172.7 | 95.71 | 125.4 | - |
| Book Value Per Share | - | 6.530 | -5.390 | -7.520 | - | - | - | - |
| Cash Flow per Share | - | -1.130 | -1.800 | -2.320 | - | - | - | - |
| Capex 1 | - | 0.59 | 0.92 | 0.27 | 0.1 | - | - | - |
| Capex / Sales | - | 137.53% | 369.6% | - | - | - | - | - |
| Announcement Date | 10/6/20 | 3/24/21 | 2/28/22 | 3/23/23 | 3/26/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.54
USD
Average target price
11.5
USD
Spread / Average Target
+352.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.25% | 122M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BCAB Stock
- Financials BioAtla, Inc.
